STIA
GEVA

Stone Toro Investment Advisers’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Stone Toro Investment Advisers’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-8,900
Closed -$564K – 162
2013
Q3 		$564K Buy
+8,900
New +$438K 0.37% 66

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Stone Toro Investment Advisers's GEVA Position: Q4 2013 in Review

Stone Toro Investment Advisers sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2013, closing a stake of 8,900 shares — an estimated $564K sold.

Stone Toro Investment Advisers first reported a position in GEVA in Q3 2013 and held it in 1 quarter. The position peaked at $564K in Q3 2013. 84 funds tracked by Wall St. Rank hold GEVA as of Q4 2013.

  • Stone Toro Investment Advisers reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • Stone Toro Investment Advisers sold 8,900 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2013, an estimated $564K.
  • Stone Toro Investment Advisers first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 1 quarter.
  • Stone Toro Investment Advisers's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $564K in Q3 2013.
  • 84 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2013.

Based on Stone Toro Investment Advisers's 13F filing for Q4 2013, filed 28 Jan 2014.